


### Amendments to the Claims

This Listing of the Claims will replace all prior versions, and listings, of claims in the application.

#### Listing of the Claims:

1. (Cancelled).
2. (Previously Presented) A compound of formula Ib



wherein

m is from 1 to 5;

$R_1$  is lower alkyl-sulfonyl; unsubstituted, mono- or di-substituted amino-sulfonyl; unsubstituted, mono- or di-substituted amino; a heterocyclic radical; lower alkyl substituted by amino, mono- or di-lower alkyl substituted amino, a heterocyclic radical, heterocyclyl-NH- or heterocyclyl-O- wherein heterocyclyl is bound to NH or O via a carbon ring atom; a radical  $R_4$ -lower alkyl-X-, wherein  $R_4$  is hydrogen, halogen, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical, and X is -S- or -O-; or a radical  $R_5$ -C(=O)-, wherein  $R_5$  is hydrogen, unsubstituted or substituted lower alkyl, free or etherified hydroxy, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical; wherein the  $R_1$  substituents are selected independently of one another if  $m > 1$ ;

R<sub>2</sub> is hydrogen, unsubstituted or substituted lower alkyl or a heterocyclic radical; and

Z is benzyloxy;

or a salt of the said compounds.

3. (Currently Amended) A compound according to claim 4, 2, in which R<sub>1</sub> is a heterocyclic radical; lower alkyl substituted by mono- or di-lower alkyl substituted amino, a heterocyclic radical, heterocyclyl-NH- or heterocyclyl-O- wherein heterocyclyl is bound to NH or O via a carbon ring atom; a radical R<sub>4</sub>-lower alkyl-X-, wherein R<sub>4</sub> is mono- or di-substituted amino, or a heterocyclic radical, and X is -S- or -O-; or a radical R<sub>5</sub>-C(=O)-, wherein R<sub>5</sub> is unsubstituted, mono- or di-substituted amino, or a heterocyclic radical; m is 1;

R<sub>2</sub> is hydrogen;

or a or a salt of the said compounds.

4. (Currently Amended) A compound according to claim 4, 2, in which R<sub>1</sub> is is a lower alkyl substituted by a di-lower alkyl substituted amino, an alkyl substituted 5- or 6- membered heterocyclyl -NH-, heterocyclyl-NH- wherein heterocyclyl is bound to NH via a carbon ring atom; a radical R<sub>4</sub>-lower alkyl-O-, wherein R<sub>4</sub> is di-substituted amino; or a radical R<sub>5</sub>-C(=O)-, wherein R<sub>5</sub> is unsubstituted, mono- or di-substituted amino, or a heterocyclic radical; m is 1;

R<sub>2</sub> is hydrogen;

or a or a salt of the said compounds.

5. (Currently Amended) A compound according to claim 4, 2, in which R<sub>1</sub> is a lower alkyl substituted by a di-lower alkyl substituted amino, or a C<sub>1</sub>-C<sub>4</sub> alkyl-substituted piperazinyl, or a pyrrolidinyl; piperidinyl wherein piperidinyl is bound to NH via a carbon ring atom; a radical R<sub>4</sub>- lower alkyl-O-, wherein R<sub>4</sub> is amino di-substituted by lower alkyl; or R<sub>5</sub>-C(=O)-, wherein R<sub>5</sub> is a C<sub>1</sub>-C<sub>4</sub> alkyl-substituted piperazinyl;

m is 1;

R<sub>2</sub> is hydrogen;

or a or a salt of the said compounds.

6. (Original) A compound chosen from the group consisting of;

{4-[3-(3-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(4-pyrrolidin-1-ylmethyl-phenyl)-amine;

{4-[3-(3-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-(4-dimethyl aminomethyl-phenyl)-amine;

(4-{4-[3-(3-Benzoyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-ylamino}-phenyl)-(4-methyl-piperazin-1-yl)-methanone;  
{4-[3-(3-Benzoyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-amine;and  
4-{4-[3-(3-Benzoyloxy-phenyl)-1H-pyrazol-4-yl]-pyrimidin-2-ylamino}-N-(2,2,6,6-tetramethyl-piperidin-4-yl)-benzamide.

7. (Original) A compound of claim 2 wherein  $R_1$  is lower alkyl substituted by amino, lower alkyl substituted by a heterocyclic radical or  $R_5-C(O)-$ .

8. (Original) A compound of claim 7 wherein  $R_1$  is lower alkyl substituted by amino.

9. (Original) A compound of claim 7 wherein  $R_1$  is lower alkyl substituted by a heterocyclic radical.

10. (Original) A compound of claim 9 wherein the alkyl portion is methylene and the heterocyclic radical is a five or six membered ring containing one or two nitrogens and is unsubstituted or substituted on one or more carbon atoms by a lower alkyl group.

11. (Original) A compound of claim 7 wherein  $R_1$  is  $R_5-C(O)-$ .

12. (Original) A compound of claim 11 wherein  $R_5$  is substituted amino or a heterocyclic radical, wherein the heterocyclic radical is a five or six membered ring containing one or two nitrogens and is unsubstituted or substituted on one or more carbon atoms by a lower alkyl group.

13. (Previously Presented) A compound of claim 7 wherein  $R_2$  is H.

14. (Previously Presented) A compound of claim 7 wherein m is 1.


15.-17. (Cancelled).

18. (Cancelled).

19. (Cancelled).

20. (Cancelled).

21. (Currently Amended) A method of treating a ~~disease which responds to inhibition of IGF-1R in a mammal~~, breast tumor which comprises administering to the mammal an effective IGF-1R inhibiting amount of a compound of formula Ib



wherein

m is from 1 to 5;

$R_1$  is lower alkyl-sulfonyl; unsubstituted, mono- or di-substituted amino-sulfonyl; unsubstituted, mono- or di-substituted amino; a heterocyclic radical; lower alkyl substituted by amino, mono- or di-lower alkyl substituted amino, a heterocyclic radical, heterocyclyl-NH- or heterocyclyl-O- wherein heterocyclyl is bound to NH or O via a carbon ring atom; a radical  $R_4$ -lower alkyl-X-, wherein  $R_4$  is hydrogen, halogen, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical, and X is a -S- or -O-; or a radical  $R_5$ -C(=O)-, wherein  $R_5$  is hydrogen, unsubstituted or substituted lower alkyl, free or etherified hydroxy, unsubstituted, mono- or di-substituted amino, or a heterocyclic radical; wherein the  $R_1$  substituents are selected independently of one another if  $m > 1$ ;

$R_2$  is hydrogen, unsubstituted or substituted lower alkyl or a heterocyclic radical; and

Z is benzyloxy;

or a pharmaceutically acceptable salt thereof.

22. (Cancelled).

23. (Currently Amended) A pharmaceutical composition which comprises a pharmaceutically effective amount of a compound of claim 4 2 and a pharmaceutically acceptable carrier.

24.-26. (Cancelled).